Investment Type: Venture Capital
Mentions in press and media 18
| Date | Title | Description |
| 18.06.2014 | Benvenue Medical secures $40M Series E to beef up manufacturing, U.S. commercialization | InterWest Partners led the round, and general partner Dr. Gil Kliman was appointed to Benvenue’s board. Other investors include DeNovo Ventures, Domain Associates, Technology Partners and Versant Ventures. Silicon Valley Bank was the sole d... |
| 19.12.2013 | We've seen the future of translational medicine ... | ... and it's disruptive A team of 110 researchers and clinicians, in therapeutics, diagnostics, devices and digital health in 25 teams at UCSF, has just shown us the future of translational medicine. It’s Lean, it’s fast, it works and it’s ... |
| 02.11.2012 | Medical device/life science startups that survive the next 36 months “will be in the catbird seat” | It noted that capital commitments to US venture funds fell in the 3rd quarter of 2012 compared with the previous three months. The number of new funds increased, reducing the concentration of the new capital that was raised. The source of t... |
| 21.06.2012 | Do Patents Really Matter To Startups? New Data Reveals Shifting Habits | Editor’s note: Leonid Kravets is a patent attorney specializing in developing IP strategy for young technology companies. He blogs on the topic at startupsip.com. Robert J. Moore is the CEO and co-founder of RJMetrics, which helps online bu... |
| 25.06.2009 | Spiracur takes $20.3M for effective wound healing | Spiracur, developer of a device used to heal small wounds effectively, has brought in $20.3 million in a second round of funding from Kleiner Perkins Caufield & Byers, New Leaf Venture Partners and De Novo Ventures, reports VentureWire.... |
| 11.06.2009 | Sans IPO, Bayhill secures $350M in Genentech licensing deal | Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bri... |
| 17.04.2009 | iScience sees $20.5M for eye surgery instruments | iScience Interventional, maker of surgical tools for eye operations, has closed a prolonged sixth round of funding at $20.5 million after facing a bit more of a challenge due to the economic climate. The money will be used to commercialize ... |
| 04.11.2008 | OncoMed nabs $93M for stem cell programs | OncoMed Pharmaceuticals, a company working to fight cancer using stem cells, added a $93 million tranche to a second round of funding that now totals $154 million. The money will be used to push its lead antibody candidate through phase-two... |
| 03.11.2008 | InSound raises $13 million more for hearing aids | Newark, Calif. hearing aid producer InSound Medical tacked $13 million more onto a fifth round of funding (now totaling $43 million). The tranche came from new investor Stanford Group, in addition to existing contributors, and is likely to ... |
| 30.07.2008 | EBR Systems gets $35 million for new style pacemaker | EBR Systems, which develops cardiac pacing devices, has raised a $35 million third round of financing. This money will help it take its product to clinical trials, according to VentureWire. Delphi Ventures led this round, with existing inve... |
Show more